Global Brain has invested in Heading Health Inc. (Heading Health), a specialised mental healthcare provider, through its GB-VIII Growth Fund Investment Limited Partnership (GB-VIII). Heading Health is a Texas-based startup that operates mental health clinics. It guides patients through personalized treatment plans incorporating psychological, psychiatric, and nutritional therapies with interventional therapies, thus ensuring optimal outcomes for patients. Heading Health provides a comprehensive range of services under one roof, including transcranial magnetic stimulation and medical psychedelics, such as Spravato® and ketamine, and more to come (subject to regulatory approvals). This comprehensive approach enables them to cater to patients with hard-to-treat mental health conditions such as treatment-resistant depression and post-traumatic stress disorder (aka PTSD). Heading Health made these treatments accessible and affordable to those in need by partnering with nearly every health insurance companies in the US. Global Brain has decided to invest in Heading Health, recognizing the potential of its comprehensive, patient-first approach and the experienced team with a proven track record. Global Brain will contribute to the growth of Heading Health, notably by leveraging its network in the pharmaceutical and other relevant industries worldwide.

About Heading Health

Location: Texas, US
CEO: Simon Tankel
Founded: September 2020
URL: https://headinghealth.com/

About GB-VIII

Name: GB-VIII Growth Fund Investment Limited Partnership
General Partner: Global Brain Corporation

About Global Brain

Location: Tokyo, Japan
Representative: Yasuhiko Yurimoto
Founded: January 1998
URL: https://globalbrains.com/

Global Brain has invested in Heading Health Inc., an insurance-based mental healthcare provider driving optimal patient outcomes